Why Levothyroxine Stops Working (The Conversion Problem Nobody Tests)

Levothyroxine is the most prescribed drug in the United States, and the logic behind it is straightforward: your thyroid isn't making enough hormone, so you replace it with a synthetic version and you measure TSH to confirm the treatment is working. For a lot of people, this works exactly as intended.

For a significant number of people, it doesn't. And the reason why comes down to a conversion step that most thyroid panels never actually measure.

Here's the full chain first, so the rest of this makes sense.

Your thyroid gland produces two hormones: T4, which is largely inactive and acts as a storage form, and T3, which is the active form that enters your cells and drives metabolism, energy production, mood regulation, and basically every process you associate with thyroid function. The problem is that your thyroid only produces about 20% of the T3 circulating in your body at any given time. The other 80% has to be manufactured elsewhere, by your liver, your kidneys, and your gut, through a process called peripheral conversion.

That conversion is handled by a class of enzymes called deiodinases, which are proteins that strip iodine atoms off T4 to produce T3. Think of T4 as a locked version of the hormone and deiodinases as the key. Without the key, you can have all the T4 in the world and your cells still don't get what they need.

When your doctor prescribes levothyroxine, which is pure synthetic T4, the entire premise of that treatment rests on the assumption that your body's conversion machinery is working. Your TSH comes back in range, so the prescription looks like it's doing its job, and the appointment ends.

But TSH is a signal from your pituitary gland, not a readout of how much usable T3 is actually reaching your tissues. Your pituitary has its own local deiodinase activity that can make it relatively insulated from what's happening in the rest of your body, so TSH can look normal even when peripheral conversion is failing elsewhere.

This is not a theoretical problem. A review published in Lancet Diabetes and Endocrinology found that patients treated with levothyroxine who had normal TSH values still showed T3 to T4 ratios 15 to 20% lower than the general population, and up to 40% of those patients remained symptomatic despite labs that looked completely fine. An online survey of hypothyroid patients reinforced this, showing prominent dissatisfaction with levothyroxine treatment even among those considered biochemically controlled.

So what actually breaks the conversion process?

The first thing to understand is that deiodinases are selenoproteins, meaning they require selenium to function. Selenium is a trace mineral, and its relationship with thyroid hormone conversion is well documented. Research in selenium-deficient patients showed that low selenium directly elevated the free T4 to T3 ratio, which is a measurable sign that conversion is impaired. When selenium is low, the deiodinase enzymes can't do their job efficiently, T4 accumulates, and T3 production falls short.

The second factor is chronic inflammation. Inflammatory signaling, particularly through cytokines like IL-6 and TNF-alpha, downregulates deiodinase activity. This matters especially in autoimmune thyroid disease, specifically Hashimoto's thyroiditis, because the ongoing immune attack on the thyroid gland creates a state of chronic local and systemic inflammation that directly suppresses the same enzymes your body depends on for the 80% conversion. So in Hashimoto's, the disease damages both the gland's direct T3 output and the peripheral machinery that should compensate for it.

The third factor is liver dysfunction. Because the liver is responsible for a large share of peripheral T4 to T3 conversion, any condition that compromises liver function, whether that's fatty liver disease, elevated liver enzymes, or poor detoxification, will reduce conversion efficiency. Similarly, gut dysbiosis, meaning an imbalance in the bacterial populations of the gut, can interfere with the portion of conversion that happens in intestinal tissue.

And then there is the genetic layer, which is where this gets particularly important for understanding why some people never respond to T4-only therapy no matter how well their TSH looks.

Between 12 and 36% of people carry a variant in a gene called DIO2, which codes for the type 2 deiodinase enzyme. This variant, depending on which study you look at, reduces the efficiency of that enzyme. Research published in the Journal of Clinical Endocrinology and Metabolism found that people with this DIO2 variant reported lower baseline psychological well-being and showed a measurably better response to combination T4 plus T3 therapy compared to T4 alone. That's a meaningful chunk of the population walking around with a structural disadvantage in their conversion pathway, being treated exclusively with the precursor hormone, and being told their labs are normal.

The enzyme variant is not a diagnosis. It is a probability distribution. But it explains why the same TSH target produces wildly different experiences for different people, and why "your labs look fine" is not always a complete answer.

What you can actually do with this information starts with testing. Asking your doctor to add free T3 to your thyroid panel gives you a direct readout of how much active hormone is circulating, rather than inferring it from a pituitary signal. If your TSH is normal and your free T3 is low, that gap is the conversion problem showing up in your labs.

If conversion is the issue, selenium is the most straightforward nutritional support for the deiodinase enzymes. A commonly studied dose is 200 micrograms per day, which is consistent with what appears in the clinical literature on selenium and thyroid function. This is worth discussing with your provider, particularly because selenium has a relatively narrow therapeutic window and excessive intake carries its own risks.

If selenium support doesn't close the gap and symptoms persist, the next conversation with your doctor is about whether T3 therapy, either as liothyronine alone or in a combination product, makes sense for you. The clinical literature, including the Lancet review, has moved meaningfully toward acknowledging that T4-only therapy has real limitations for a real percentage of patients.

Most people starting levothyroxine are never told that the medication only addresses the 20% their thyroid was producing directly and assumes the 80% takes care of itself. Most people are never told that assumption can fail, or that there are testable, addressable reasons why it fails.

Treating a lab value and treating a person are not the same thing, and understanding where that gap comes from is the first step toward closing it.

---

References

1. Bianco AC, Kim BW. Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest. 2006;11610:2571-2579. PMID: 17016550. Source
2. Endotext NCBI Bookshelf. Thyroid Hormone Synthesis and Secretion: "The thyroid gland produces approximately 20% of total daily T3 production, with the remaining 80% arising from peripheral deiodination of T4." Source
3. Salvatore D, Porcelli T, Ettleson MD, Bianco AC. The relevance of T3 in the management of hypothyroidism. Lancet Diabetes Endocrinol. 2022;10(5):366-372. DOI: 10.1016/S2213-8587(22)00004-3.
4. Peterson SJ, Cappola AR, Castro MR, et al. An online survey of hypothyroid patients demonstrates prominent dissatisfaction. Thyroid. 2019;295:707-721. PMID: 29620972. Source
5. Panicker V, Saravanan P, Vaidya B, et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy. JCEM. 2009;945:1623-1629. PMID: 19190113. Source
6. Kobayashi R, Hasegawa Y, Kawaguchi T, et al. Thyroid function in patients with selenium deficiency exhibits high free T4 to T3 ratio. Clin Pediatr Endocrinol. 2021;30(1):19-26. DOI: 10.1297/cpe.30.19.
7. Ventura M, Melo M, Carrilho F. Selenium and thyroid disease: from pathophysiology to treatment. Int J Endocrinol. 2017;2017:1297658. PMID: 28255299. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness